France moves forward on pharmacovigilance overhaul
This article was originally published in SRA
Executive Summary
As part of its ongoing review into the French pharmacovigilance and regulatory system, France's General Inspectorate of Social Affairs, IGAS, has met with the European Medicines Agency to discuss pharmacovigilance in the EU1. IGAS's review is expected to lead to an overhaul of the current system and considerable change for pharmaceutical companies.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.